RE:Oncolytics Biotech® Letter to Shareholders - Update".... China and the other areas in which Adlai Nortye anticipates commercializing pelareorep are among the largest in the world and growing rapidly," said Andrew de Guttadauro, President of Oncolytics Biotech U.S. and Global Head of Business Development. "With the bridging trial entering its final cohort (March 2022) less than six months after dosing began, Adlai is making major strides towards satisfying the regulatory criteria needed to accelerate pelareorep's development in China. The trial also continues to generate positive safety data, which will serve us well as we collaborate with Adlai Nortye to advance pelareorep towards approval in key global markets."
[Adlai Nortye guided that it anticipates moving to a Phase III with pelareorep + paclitaxel in mBC in Q2 2022.]
https://ir.oncolyticsbiotech.com/press-releases/detail/564/oncolytics-biotech-partner-adlai-nortye-advances-chinese